Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III trial of BAY 81-8973 prophylaxis in children with severe hemophilia A
2010-021781-29Phase 3Completed
- Sponsor
- Bayer
- Start
- Dec 2010
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of octocog alfa in hemophilia A, sponsored by Bayer. Primary endpoint: Annualized number of total bleeds during prophylaxis. Started Dec 2010; status: completed.
02
Drugs
octocog alfa
03
Conditions
hemophilia A
Beyond the preview
Go deeper on 2010-021781-29.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-021781-29.